AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22147094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19505297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention protocol applied to overweight children, including up to three counselling sessions for parents
Number of subjects: 44
Study 19505297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 17216745 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 50 mg twice daily for seven days
Number of subjects: 38
Study 17216745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12628617 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (4.8 g/day)
Number of subjects: 44
Study 12628617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg/day)
Number of subjects: 44
Study 12628617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10711582 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐risk reduction (HIV‐RR) intervention
Number of subjects: 102
Study 10711582 — intervention group
Group type: COMPARATOR
Intervention: Health‐promotion control group
Number of subjects: 102
Study 9398896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (antibiotics)
Number of subjects: 30
Study 9398896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1593661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched tapering and aftercare assistance program (available to 58 clients)
Number of subjects: 114
Study 1593661 — intervention group
Group type: COMPARATOR
Intervention: Written materials only (received by 56 clients)
Number of subjects: 114
Study 6379122 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (MVPP)
Number of subjects: 56
Study 6379122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy (MVPP + radiotherapy)
Number of subjects: 56
Study 31265100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 698
Study 31265100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5/5 mg
Number of subjects: 698
Study 31265100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 698
Study 28429147 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day for 15 days)
Number of subjects: 0
Study 28429147 — intervention group
Group type: COMPARATOR
Intervention: Cumulative docetaxel exposure
Number of subjects: 0
Study 28429147 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (younger men 55-68 years)
Number of subjects: 0
Study 28429147 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and ex-smokers
Number of subjects: 0
Study 28429147 — intervention group
Group type: COMPARATOR
Intervention: Mood status
Number of subjects: 0
Study 28429147 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin levels
Number of subjects: 0
Study 28429147 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnolence and muscle fatigue
Number of subjects: 0
Study 28929697 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine 300 mg (tid) in addition to general therapy
Number of subjects: 120
Study 28929697 — intervention group
Group type: COMPARATOR
Intervention: General therapy according to the latest guidelines
Number of subjects: 120
Study 25041326 — intervention group
Group type: COMPARATOR
Intervention: Chemonucleolysis only (oxygen‐ozone combined with collagenase)
Number of subjects: 192
Study 25041326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis combined with psoas compartment block (PCB)
Number of subjects: 192
Study 25041326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 192
Study 25041326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis combined with PCB (Group B)
Number of subjects: 192
Study 22112606 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 86
Study 22112606 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir‐boosted protease inhibitor (PI/r)
Number of subjects: 86
Study 19528867 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Resistance Exercise (HRE) protocol - parallel back squats at 40, 50, 60, and 80% of 1-repetition maximum after dynamic stretches
Number of subjects: 10
Study 19528867 — intervention group
Group type: COMPARATOR
Intervention: Control treatment - dynamic stretches only
Number of subjects: 10
Study 17558827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day with Cognitive Behavioral Therapy (CBT)
Number of subjects: 154
Study 17558827 — intervention group
Group type: COMPARATOR
Intervention: Bupropion 300 mg/day with Supportive Therapy (ST)
Number of subjects: 154
Study 17558827 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Cognitive Behavioral Therapy (CBT)
Number of subjects: 154
Study 17558827 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Supportive Therapy (ST)
Number of subjects: 154
Study 17558827 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication compliance
Number of subjects: 154
Study 15366592 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (ICWM) with Kangmin Xiaoban Yin for 7-10 days
Number of subjects: 176
Study 15366592 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (ICWM)
Number of subjects: 176
Study 15366592 — intervention group
Group type: COMPARATOR
Intervention: Control group (Western routine therapy)
Number of subjects: 176
Study 11464427 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling delivered by trained counselors (HOPP)
Number of subjects: 0
Study 11464427 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-service intervention delivered by providers and staff (STORK)
Number of subjects: 0
Study 9893769 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms formoterol fumarate
Number of subjects: 31
Study 9893769 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol fumarate
Number of subjects: 31
Study 9893769 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol fumarate
Number of subjects: 31
Study 9893769 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 micrograms formoterol fumarate
Number of subjects: 31
Study 9893769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7992905 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 0 micrograms
Number of subjects: 0
Study 7992905 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 5 micrograms
Number of subjects: 0
Study 7992905 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 micrograms
Number of subjects: 0
Study 7992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 micrograms
Number of subjects: 0
Study 7992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 40 micrograms
Number of subjects: 0
Study 7992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 50 micrograms
Number of subjects: 0
Study 3051508 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin + Erdosteine
Number of subjects: 24
Study 3051508 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin alone
Number of subjects: 24
Study 4888877 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 mug.
Number of subjects: 24
Study 4888877 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline sulphate 1,000 mug.
Number of subjects: 24
Study 4888877 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline sulphate 1,500 mug.
Number of subjects: 24
Study 4888877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31087164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 60
Study 31087164 — intervention group
Group type: COMPARATOR
Intervention: X-ray guidance
Number of subjects: 60
Study 28105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DSPN
Number of subjects: 48
Study 25586870 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal additions to consent for standard care
Number of subjects: 0
Study 25586870 — intervention group
Group type: COMPARATOR
Intervention: In-depth research consent
Number of subjects: 0
Study 25586870 — intervention group
Group type: COMPARATOR
Intervention: No research consent
Number of subjects: 0
Study 22695137 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 49
Study 22695137 — intervention group
Group type: COMPARATOR
Intervention: Flexibility training
Number of subjects: 49
Study 21462725 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) plus access to a nurse case manager (NCM)
Number of subjects: 165
Study 21462725 — intervention group
Group type: COMPARATOR
Intervention: Diabetes self-management education (DSME) only
Number of subjects: 165
Study 19394478 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet records
Number of subjects: 244
Study 19394478 — intervention group
Group type: EXPERIMENTAL
Intervention: Arizona Food Frequency Questionnaire
Number of subjects: 244
Study 19394478 — intervention group
Group type: COMPARATOR
Intervention: Diet records and Arizona Food Frequency Questionnaire
Number of subjects: 244
Study 12963552 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with TBI
Number of subjects: 36
Study 12963552 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 36
Study 11121627 — intervention group
Group type: EXPERIMENTAL
Intervention: Biafine
Number of subjects: 172
Study 11121627 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 172
Study 9074535 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg orally 12 hr and 1 hr before the study)
Number of subjects: 10
Study 9074535 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg orally 12 hr and 1 hr before the study) with dipyridamole
Number of subjects: 10
Study 9074535 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no metoprolol)
Number of subjects: 10
Study 8189215 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual information provided before or immediately after seeing the film
Number of subjects: 185
Study 8189215 — intervention group
Group type: COMPARATOR
Intervention: Contextual information provided after a week's retention interval
Number of subjects: 185
Study 2870216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Metipranolol
Number of subjects: 0
Study 31748300 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based music programme plus standard care (SC)
Number of subjects: 495
Study 31748300 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based reading programme plus standard care (SC)
Number of subjects: 495
Study 31748300 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 495
Study 29411166 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF) as a socket plug
Number of subjects: 48
Study 29411166 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaster of Paris (POP) as bone substitute with PRF
Number of subjects: 48
Study 29411166 — intervention group
Group type: COMPARATOR
Intervention: Control group with figure of eight suture only
Number of subjects: 48
Study 27756286 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° feedback from peers, standardized patients (SPs), and a trainer during communication skills training (CST)
Number of subjects: 34
Study 27756286 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback by standardized patients (SPs)
Number of subjects: 34
Study 27756286 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback by trainer
Number of subjects: 34
Study 27756286 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback by colleagues
Number of subjects: 34
Study 27756286 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical introduction
Number of subjects: 34
Study 27756286 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory card
Number of subjects: 34
Study 24827123 — intervention group
Group type: COMPARATOR
Intervention: ABVD (8 cycles)
Number of subjects: 150
Study 24827123 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP (4 escalated cycles ≥ 4 baseline)
Number of subjects: 150
Study 22541840 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan Potassium Tablets 50 mg
Number of subjects: 60
Study 22541840 — intervention group
Group type: COMPARATOR
Intervention: Cozaar® Tablets 50 mg
Number of subjects: 60
Study 19271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Number of subjects: 0
Study 19271158 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy (5×5 Gy)
Number of subjects: 0
Study 19271158 — intervention group
Group type: COMPARATOR
Intervention: Combined radiochemotherapy
Number of subjects: 0
Study 19271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 17526461 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOx (1.2 g)
Number of subjects: 79
Study 17526461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg)
Number of subjects: 79
Study 17526461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 79
Study 17526461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E
Number of subjects: 79
Study 12948801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12948801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic treatment (zolpidem, triazolam, zopiclone, brotizolam)
Number of subjects: 47
Study 11153594 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive mandibular advancement
Number of subjects: 10
Study 11153594 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary mandibular advancement
Number of subjects: 10
Study 11153594 — intervention group
Group type: COMPARATOR
Intervention: Resting mandibular position
Number of subjects: 10
Study 9356866 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (800 micrograms/day)
Number of subjects: 52
Study 9356866 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin (210 mg/day)
Number of subjects: 52
Study 9356866 — intervention group
Group type: COMPARATOR
Intervention: no drug treatment (control group)
Number of subjects: 52
Study 8222746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (2 mg/ml) ear drops twice daily for 7 days
Number of subjects: 30
Study 8222746 — intervention group
Group type: COMPARATOR
Intervention: Combined antibiotic (oxytetracycline 5 mg/ml, polymyxin B 10,000 units/ml, hydrocortisone 15 mg/ml) ear drops twice daily for 7 days
Number of subjects: 30
Study 3511930 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg slow release tablets once daily for at least 2 weeks, plus 15 mg i.v. shortly before anaesthesia)
Number of subjects: 30
Study 3511930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets and saline)
Number of subjects: 30
Study 3511930 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 30
Study 3511930 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Placebo
Number of subjects: 30
Study 31311102 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal protein content at 11% kcal protein
Number of subjects: 21
Study 31311102 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal protein content at 23% kcal protein
Number of subjects: 21
Study 31311102 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal protein content at 31% kcal protein
Number of subjects: 21
Study 31311102 — intervention group
Group type: EXPERIMENTAL
Intervention: Women taking OCP
Number of subjects: 21
Study 31311102 — intervention group
Group type: EXPERIMENTAL
Intervention: Women without OCP
Number of subjects: 21
Study 29350710 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured strength training program introduced during hospitalization and continued for six weeks after release
Number of subjects: 37
Study 27927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 44
Study 27927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength training
Number of subjects: 44
Study 23856201 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 31
Study 23856201 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus downsizing mitral ring annuloplasty
Number of subjects: 31
Study 22588156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasisulam sodium (LY573636 sodium) administered as a 2-hour infusion every 21 days at a Cmax target dose of 420 µg/ml
Number of subjects: 32
Study 22588156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasisulam sodium (LY573636 sodium) administered at a lower Cmax target dose of 380 µg/ml
Number of subjects: 32
Study 20209303 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (received instructions at all visits)
Number of subjects: 60
Study 20209303 — intervention group
Group type: COMPARATOR
Intervention: Control group (received instructions only at the first visit)
Number of subjects: 60
Study 20209303 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 60
Study 20209303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 18716159 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d quercetin for 2 weeks
Number of subjects: 35
Study 18716159 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d quercetin for 2 weeks
Number of subjects: 35
Study 18716159 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/d quercetin for 2 weeks
Number of subjects: 35
Study 15943544 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal methylphenidate (MPH) 12.5 cm²
Number of subjects: 27
Study 15943544 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal methylphenidate (MPH) 25.0 cm²
Number of subjects: 27
Study 15943544 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal methylphenidate (MPH) 37.5 cm²
Number of subjects: 27
Study 15943544 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification (BMOD)
Number of subjects: 27
Study 15943544 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (MPH + BMOD)
Number of subjects: 27
Study 15943544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12801361 — intervention group
Group type: COMPARATOR
Intervention: Miconazole (Daktarin(R) gel oral)
Number of subjects: 60
Study 12801361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel of Punica granatum Linné (pomegranate)
Number of subjects: 60
Study 10591258 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser ablation of the prostate (CLAP) using Nd:YAG laser treatment
Number of subjects: 37
Study 10591258 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 37
Study 10591258 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser ablation of the prostate (CLAP)
Number of subjects: 37
Study 8915274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast ingestion group with 20 mg of oral metoclopramide
Number of subjects: 64
Study 8915274 — intervention group
Group type: COMPARATOR
Intervention: Standard ingestion group without additional drugs
Number of subjects: 64
Study 1667048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (KABI) 300 anti‐Xa U/kg/24h subcutaneously for 6‐10 days
Number of subjects: 72
Study 1667048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (KABI) 240‐360 anti‐Xa U/kg/24h subcutaneously for 6‐10 days
Number of subjects: 72
Study 6416593 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus booklet plus the offer of nicotine gum
Number of subjects: 1938
Study 6416593 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus booklet
Number of subjects: 1938
Study 6416593 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention controls
Number of subjects: 1938
Study 6416593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (self-selected subgroup using more than one box of 105 pieces)
Number of subjects: 1938
Study 30744092 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive leaf extract (OLE) supplementation (100 mg oleuropein equivalent to 20 g of olive leaf) for nine weeks.
Number of subjects: 32
Study 30744092 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for nine weeks.
Number of subjects: 32
Study 28654312 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai chi combined with health education twice weekly for 12 weeks
Number of subjects: 43
Study 28654312 — intervention group
Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 43
Study 26239288 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-steered treat-to-target (T2T) strategy
Number of subjects: 0
Study 25816655 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-port laparoscopic cholecystectomy
Number of subjects: 118
Study 25816655 — intervention group
Group type: COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy (control group)
Number of subjects: 118
Study 22932146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 86
Study 22932146 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 86
Study 19887279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg after obtaining 2 responses, 4 mg/kg with post‐tetanic count between 1 and 3 responses, 12 to 16 mg/kg for rescue reversal)
Number of subjects: 0
Study 17383057 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit vaccine (Sub/MF59)
Number of subjects: 238
Study 17383057 — intervention group
Group type: COMPARATOR
Intervention: Conventional subunit vaccine (Subunit)
Number of subjects: 238
Study 12708121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayam training (nadishuddhi, mukh-bhastrika, pranav and savitri pranayams) for 20 minutes daily for 3 months
Number of subjects: 24
Study 12708121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pranayam training)
Number of subjects: 24
Study 9892329 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg warfarin
Number of subjects: 53
Study 9892329 — intervention group
Group type: COMPARATOR
Intervention: 10 mg warfarin
Number of subjects: 53